AARD News & Events

Hopes for de-escalation in the Middle East conflict helped restore positive sentiment as President Trump's Truth Social post that strikes on Iranian energy infrastructure would be postponed after "productive" talks with Tehran boosted equities and dented geopolitical premium in the energy markets.  Consumer Discretionary and Materials were the best performing areas on the benchmark S&P 500, though all 11 sectors ended Monday in the positive - including Energy in spite of Oil prices falling back below $90 per barrel.  In the opening hour of the evening session, S&P 500 futures  are up another 0.2% and Nasdaq 100 is trading up 0.3% while WTI Crude is just off the closing lows above $89.  In precious metals, risk aversion which had boosted USD and punished Gold and Silver prices has reversed, and the two contracts are trading firmer around $4.435 and $70 per ounce respectively.Among the key headlines of the afterhours session continued to remind investors that the primary source of concern are still present.  Core Labsissued a below-consensus Q1 pre-announcement as the company cited regional instability in the Middle East, including client-driven project delays, travel constraints, and supply-chain disruptions. Private Credit worries also cropped up via reports from Bloomberg stating that Apollo Globalhas joined some of the other asset managers in capping private equity redemptions due to high volume of requests by investors to liquidate their positions.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -BARKup 6.4%Bionano Genomicsup 4.1%DOWN AFTER EARNINGS -Core Laboratoriesdown 1.8% after Q1 pre-announcementAardvark Therapeuticsdown 1.5%ALSO LOWER -Comtech Telecommunicationsdown 3.9% after equity offeringApollo Global Managementdown 2.1% after Bloomberg report of capped private equity redemptions

Aardvark Therapeutics files $400M mixed securities shelf

As of December 31, 2025, Aardvark had cash, cash equivalents and short-term investments of $110M, compared to $73.7M as of December 31, 2024. Based on current operating plans, Aardvark believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund projected operations into the second quarter of 2027. "Patient safety will always be our highest priority, and we are actively engaging with the FDA with urgency to determine the best path forward for our programs. As we evaluate next steps, we want to thank the Prader-Willi Syndrome community for its collaboration throughout this process. The community's strength and tenacity continue to inspire our work," said Tien Lee, founder and CEO of Aardvark. "With positive clinical data, an encouraging safety profile from previous trials and our recently developed understanding of the clear blood plasma exposure-response relationship with reversible cardiac QRS prolongation, we have confidence in ARD-101. We strongly believe that ARD-101 retains its potential as a differentiated therapeutic option for hyperphagia in individuals living with PWS. We hope to resume the PWS development program in a timely manner and expect to provide further guidance on each of our programs in the second quarter of 2026."